Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, upadacitinib and filgotinib, are
increasingly used in the treatment of rheumatoid arthritis (RA). There has been debate about …

Objectives Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib
versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with …

Juvenile idiopathic arthritis (JIA) is a heterogeneous group of diseases with probably
differential underlying physiopathology. Despite the revolutionary era of biologics, some …

Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management
recommendations addressing the most recent developments in the field. Methods An …

Anti-melanoma differentiation-associated protein 5 (MDA5) antibody-positive
dermatomyositis (MDA5-DM) is frequently complicated with rapidly progressive-interstitial …

Rheumatoid arthritis (RA) is one of the most common immune mediated inflammatory
diseases. People with rheumatoid arthritis present with pain, swelling, and stiffness that …

Janus kinase inhibitors (JAKis) are the most recent new drug class to arrive to the market for
rheumatoid arthritis (RA) treatment. While they have proven to be a very effective treatment …

Objective The mechanism by which Notopterygium (NE) regulates the nucleotide‐binding,
oligomerization domain (NOD)‐like receptor family and pyrin domain-containing 3 (NLRP3) …

Objectives To compare the incidence of major adverse cardiovascular events (MACEs),
cancer and infective complications in RA patients using Janus kinase (JAKis) and TNF …

Rheumatoid arthritis (RA) is a highly prevalent autoimmune disorder. The pathogenesis of
the disease is complex and involves various cellular populations, including fibroblast-like …